Warning: The NCBI web site requires JavaScript to function. more...
Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.
Madrid MA, Lo RW.
Breast Cancer Res. 2004;6(5):R593-600. Epub 2004 Jul 29.
Related citations
HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.
Moelans CB, de Weger RA, van Blokland MT, Ezendam C, Elshof S, Tilanus MG, van Diest PJ.
Cell Oncol. 2009;31(1):1-10.
Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
Kim GY, Oh YL.
Cytopathology. 2004 Dec;15(6):315-20.
[Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
Zhang GH, Shi DR, Liang XM, Hou JH, Kang SY, Zhu WD, Li XB, Shao Y, Chen LR, Zhou Y.
Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):580-3. Chinese.
Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome.
Peiró G, Mayr D, Hillemanns P, Löhrs U, Diebold J.
Mod Pathol. 2004 Mar;17(3):227-87.
Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, Nikolić-Vukosavljević D.
Pathol Int. 2005 Jun;55(6):318-23.
Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.
Dandachi N, Dietze O, Hauser-Kronberger C.
Lab Invest. 2002 Aug;82(8):1007-14.
HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A, Xu B, Ayata G, Baiyee D, Wallace J, Wertheimer M, Edmiston K, Khan A.
Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):132-7.
Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Mayr D, Heim S, Weyrauch K, Zeindl-Eberhart E, Kunz A, Engel J, Kirchner T.
Histopathology. 2009 Dec;55(6):716-23. Epub .
Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
Johnson CJ, Barry MB, Vasef MA, Deyoung BR.
Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):54-8.
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J.
Br J Cancer. 2003 May 19;88(10):1587-91.
HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL, Jamehdor MR, Arber JM.
Mod Pathol. 2000 Aug;13(8):866-73.
HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T.
Anticancer Res. 2006 Jan-Feb;26(1B):647-53.
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J.
Am J Pathol. 2000 Nov;157(5):1467-72.
HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
Sáez A, Andreu FJ, Seguí MA, Baré ML, Fernández S, Dinarés C, Rey M.
Breast. 2006 Aug;15(4):519-27. Epub 2005 Nov 14.
The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, Park SY.
J Clin Pathol. 2008 Mar;61(3):317-21. Epub 2007 Aug 30.
Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
Vocaturo A, Novelli F, Benevolo M, Piperno G, Marandino F, Cianciulli AM, Merola R, Donnorso RP, Sperduti I, Buglioni S, Mottolese M.
Oncologist. 2006 Sep;11(8):878-86.
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ.
J Clin Oncol. 2000 Nov 1;18(21):3651-64.
Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
Hammock L, Lewis M, Phillips C, Cohen C.
Hum Pathol. 2003 Oct;34(10):1043-7.
Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R, Apple SK, He J, Gornbein JA, Chang HR.
Breast J. 2005 Nov-Dec;11(6):433-9.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on